MA34389B1 - Nouvelles aminopyrazoloquinazolines - Google Patents
Nouvelles aminopyrazoloquinazolinesInfo
- Publication number
- MA34389B1 MA34389B1 MA35577A MA35577A MA34389B1 MA 34389 B1 MA34389 B1 MA 34389B1 MA 35577 A MA35577 A MA 35577A MA 35577 A MA35577 A MA 35577A MA 34389 B1 MA34389 B1 MA 34389B1
- Authority
- MA
- Morocco
- Prior art keywords
- aminopyrazoloquinazolines
- new
- groups
- general formula
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention englobe les composés de formule générale (I) où les groupements R
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170683 | 2010-07-23 | ||
PCT/EP2011/062683 WO2012010704A1 (fr) | 2010-07-23 | 2011-07-22 | Nouvelles aminopyrazoloquinazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34389B1 true MA34389B1 (fr) | 2013-07-03 |
Family
ID=43037625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35577A MA34389B1 (fr) | 2010-07-23 | 2011-07-22 | Nouvelles aminopyrazoloquinazolines |
Country Status (23)
Country | Link |
---|---|
US (1) | US8735386B2 (fr) |
EP (1) | EP2595987B1 (fr) |
JP (1) | JP5991974B2 (fr) |
KR (1) | KR20130132394A (fr) |
CN (1) | CN103097388A (fr) |
AP (1) | AP2012006640A0 (fr) |
AR (1) | AR082850A1 (fr) |
AU (1) | AU2011281504A1 (fr) |
BR (1) | BR112013000107A2 (fr) |
CA (1) | CA2803467A1 (fr) |
CL (1) | CL2012003745A1 (fr) |
CO (1) | CO6670575A2 (fr) |
EA (1) | EA201201661A1 (fr) |
EC (1) | ECSP13012448A (fr) |
GE (1) | GEP20156289B (fr) |
MA (1) | MA34389B1 (fr) |
MX (1) | MX2013000821A (fr) |
PE (1) | PE20131143A1 (fr) |
PH (1) | PH12013500152A1 (fr) |
SG (1) | SG187548A1 (fr) |
TW (1) | TW201217380A (fr) |
UY (1) | UY33526A (fr) |
WO (1) | WO2012010704A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2807166B1 (fr) | 2012-01-23 | 2016-04-06 | Boehringer Ingelheim International GmbH | 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines en tant qu'inhibiteurs igf-1r/ir |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
SG10201809189UA (en) * | 2013-11-15 | 2018-11-29 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use |
SMT202000696T1 (it) | 2015-01-30 | 2021-01-05 | Oncoceutics Inc | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9- esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-one e suoi sali e loro uso in terapia |
EP3294742B1 (fr) * | 2015-05-13 | 2020-01-08 | Boehringer Ingelheim International GmbH | Nouveaux (5,8-diméthyl-9-phényle-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolein-2-yl)-(1h-pyrazol-3-yl)-amines et leurs dérivés comme inhibiteurs de la igf-1r/ir |
JP6905069B2 (ja) * | 2016-11-11 | 2021-07-21 | 上海海雁醫藥科技有限公司 | ピリジルアミノ置換へテロ三環式化合物並びにその製造方法及び医薬用途 |
DK3632904T3 (da) * | 2017-05-26 | 2022-07-25 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | URAT1-inhibitorer til at fremme urinsyreudskillelse |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
JP2021521282A (ja) * | 2018-04-24 | 2021-08-26 | 上海海雁医薬科技有限公司Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Cdk4/6阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
EP3917514A4 (fr) * | 2019-01-30 | 2023-02-22 | Yale University | Composés, compositions et méthodes de traitement de la fibrose |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
BR112021016960A2 (pt) * | 2019-03-07 | 2021-11-23 | BioNTech SE | Processo para a preparação de uma imidazoquinolina substituída |
WO2020205560A1 (fr) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Composés sulfonylamides utilisés comme inhibiteurs de la cdk2 |
JP2022531094A (ja) * | 2019-04-19 | 2022-07-06 | ファウント バイオ, インコーポレイテッド | 皮膚内への活性剤の送達および保持 |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
EP4013750A1 (fr) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2 |
CA3157681A1 (fr) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Amines bicycliques utilisees en tant qu'inhibiteurs de cdk2 |
MX2022015410A (es) | 2020-06-05 | 2023-03-13 | Kinnate Biopharma Inc | Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos. |
CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
JP7545622B2 (ja) * | 2021-02-08 | 2024-09-05 | 江蘇星盛新輝医薬有限公司 | 5,6-ジドヒロチエノ[3,4-h]キナゾリン系化合物 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1118460C (zh) * | 1995-10-02 | 2003-08-20 | 弗·哈夫曼-拉罗切有限公司 | 作为5HTzc-受体拮抗剂的嘧啶衍生物 |
RS20050944A (en) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/fr active Application Filing
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/fr active Active
- 2011-07-22 CA CA2803467A patent/CA2803467A1/fr not_active Abandoned
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Application Discontinuation
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 PH PH1/2013/500152A patent/PH12013500152A1/en unknown
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011281504A1 (en) | 2013-01-10 |
EA201201661A1 (ru) | 2013-07-30 |
EP2595987A1 (fr) | 2013-05-29 |
US20120238542A1 (en) | 2012-09-20 |
JP5991974B2 (ja) | 2016-09-14 |
SG187548A1 (en) | 2013-03-28 |
AP2012006640A0 (en) | 2012-12-31 |
UY33526A (es) | 2012-02-29 |
GEP20156289B (en) | 2015-05-25 |
PE20131143A1 (es) | 2013-10-23 |
EP2595987B1 (fr) | 2018-04-18 |
TW201217380A (en) | 2012-05-01 |
BR112013000107A2 (pt) | 2016-05-17 |
CA2803467A1 (fr) | 2012-01-26 |
US8735386B2 (en) | 2014-05-27 |
MX2013000821A (es) | 2013-05-30 |
CN103097388A (zh) | 2013-05-08 |
PH12013500152A1 (en) | 2013-02-18 |
AR082850A1 (es) | 2013-01-16 |
CL2012003745A1 (es) | 2013-05-31 |
JP2013532652A (ja) | 2013-08-19 |
ECSP13012448A (es) | 2013-03-28 |
CO6670575A2 (es) | 2013-05-15 |
KR20130132394A (ko) | 2013-12-04 |
WO2012010704A1 (fr) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
JOP20180103A1 (ar) | مركب صيدلاني | |
MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
CR20130045A (es) | Compuestos terapéuticos | |
CY1119105T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
CR20120295A (es) | Triazolopiridinas | |
CR20130369A (es) | Novedosos derivados heterocíclicos | |
UY34445A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
MA35357B1 (fr) | Composes de type anilines | |
MA35049B1 (fr) | Triazolopyridines | |
CR20120297A (es) | Espironucleósidos uracílicos oxetánicos | |
CR20120113A (es) | (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer | |
UA110338C2 (xx) | Хімічні сполуки | |
UY34825A (es) | Síntesis de compuestos heterocíclicos | |
AU2011232516A8 (en) | Chemical compounds | |
TR201900038T4 (tr) | GPR6'nın tetrahidropiridopirazin modülatörleri. | |
CR20120637A (es) | Triazolopiridinas sustituidas | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
EA200900945A1 (ru) | Новый способ синтеза агомелатина |